主治医师，北京市科技新星获得者

北京大学医学部肿瘤学博士毕业(2013)。北京大学肿瘤医院暨北京市肿瘤防治研究所胸部肿瘤内一科主治医师。2014年入选北京市科技新星，2014年入选北京市优秀人才培养资助计划”。

电话：88196456 邮箱：jie_969@163.com

主要研究方向、成就

致力于肺癌相关分子标志物如EGFR、K-ras、T790M、C-MET、EML4-ALK等组织和外周血的动态、定量检测平台的建立，结果广泛应用于临床。对EGFR突变及T790M突变进行数字化PCR等定量分析，发现原发性T790M突变以及定量分析是EGFR-TKI治疗的预测指标。探讨EGFR-TKI的耐药机制，包括肿瘤异质性，发现化疗导致的EGFR突变频率的改变是由肿瘤异质性导致的，异质性是导致EGFR-TKI耐药的机制之一。研究肺癌循环肿瘤单细胞水平全基因组的变化模式及其意义，发现单个循环肿瘤细胞的CNV模式具有可重复性，稳定性以及个体特异性等特点，为实现CTC为基础的肿瘤诊断提供了潜在的可能手段;所进行的单细胞水平的CTC基因组分析可以为肿瘤的个体化治疗提供无创、精准、实时的生物学信息。

承担课题

1. 国家自然科学基金委青年基金：基于EGFR信号通路的‘个体化’逆转贝伐单抗耐药的实验研究分子肿瘤学(#81101778，2012-2014)

2. 国家自然科学基金委面上项目：肺癌病理表型转化预测模型及分子机制(#81472206，2015-2018)

3. 北京市优秀人才培养资助计划：EGFR突变型肺鳞癌对EGFR-TKIs的敏感性分析及分子机制探讨(#2013D003034000019，2014-2015)

4. 北京市科技新星计划：EGFR突变型肺鳞癌对EGFR-TKIs的敏感性分析及分子机制研究(#xx2014B051，2014-2017)

发表的代表性论文(第一#或责任作者*)

1. Zhijie Wang, Rui Chen, Shuhang Wang, Jia Zhong, Meina Wu, Jun Zhao, Jianchun Duan, Minglei Zhuo, Tongtong An, Yuyan Wang, Hua Bai, Jie Wang* (2014) Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC. PLOS ONE, 8(11):e110780

2. Xiaohui Nia#, Minglei Zhuo#, Zhe Su#, Jianchun Duan#, Yan Gao#, Zhijie Wang#, Chenghang Zong#, Hua Bai, Alec R. Chapman, Jun Zhao, Liya Xu, Tongtong An, Qi Ma, Yuyan Wang, Meina Wu, Yu Sun, Shuhang Wang, Zhenxiang Li, Xiaodan Yang, Jun Yong, Xiao-Dong Su, Youyong Lu, Fan Bai, X. Sunney Xie*, and Jie Wang* (2013) Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. PNAS 110: 21083-8

3. Hua Bai#, Zhijie Wang#, Yuyan Wang, Minglei Zhuo, Qinghua Zhou, Jianchun Duan, Lu Yang, Meina Wu, Tongtong An, Jun Zhao, Jie Wang* (2013) Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLOS ONE 8:e54170.

4. Hua Bai#, Zhijie Wang#, Keneng Chen, Jun Zhao, J. Jack Lee, Shuhang Wang, Qinghua Zhou, Minglei Zhuo, Li Mao, Tongtong An, Jianchun Duan, Lu Yang, Meina Wu, Zhen Liang, Yuyan Wang, Xiaozheng Kang, and Jie Wang* (2012) Influence of chemotherapy on EGFR mutation status among patients with non–small-cell lung cancer. J Clin Oncol 30:3077-83

5. Zhen Huang#, ZhijieWang#, Hua Bai, Meina Wu, Tongtong An, Jun Zhao, Lu Yang, Jianchun Duan, Minglei Zhuo, Yuyan Wang, Shuhang Wang and Jie Wang. (2012) The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thoracic Cancer 3:334-40

6. Zhijie Wang#, Xuchao Zhang#, Hua Bai, Jun Zhaoa, Minglei Zhuo, Tongtong An, Jianchun Duan, Lu Yang, Meina Wu, Shuhang Wang, Yuyan Wang, Yilong Wu and Jie Wang* (2012) EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. Oncology 83:248-56

7. Zhijie Wang, Tongtong An, Tony Mok, Lu Yang, Hua Bai, Jun Zhao, Jian chun Duan, Mei-na Wu, Yuyan Wang, Pingping Li, Hong Sun, Ping Yang and iie Wang. (2011) Immediate versus treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer. Chin J Cancer Res 23(2):112-7.